It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Universal Pictures will release “Atlantis” wide on May 9, 2025. While plot details remain under wraps, the film is described as an expedition into the summer of 1977 in the Virginia Beach ...

Universal has dated the Pharrell Williams-Michel Gondry musical feature Atlantis for May 9, 2025. The pic is based on Williams’ childhood at the Virginia Beach Atlantis Apartments during the ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

The 2024 Battle 4 Atlantis bracket was announced today and Indiana women’s basketball will open the event against Columbia on Saturday, November 23, on Paradise Island. Baylor, Southern Miss ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

Although the film’s plot has yet to be revealed, it’s described as a coming-of-age musical set in the summer of 1977 in Virginia Beach in a neighborhood like the one where Pharrell grew up ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...